217 related articles for article (PubMed ID: 15507522)
1. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532.
El-Daly H; Kull M; Zimmermann S; Pantic M; Waller CF; Martens UM
Blood; 2005 Feb; 105(4):1742-9. PubMed ID: 15507522
[TBL] [Abstract][Full Text] [Related]
2. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
[TBL] [Abstract][Full Text] [Related]
3. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532).
El Daly H; Martens UM
Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817
[TBL] [Abstract][Full Text] [Related]
4. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
Mueller S; Hartmann U; Mayer F; Balabanov S; Hartmann JT; Brummendorf TH; Bokemeyer C
Invest New Drugs; 2007 Dec; 25(6):519-24. PubMed ID: 17534576
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with emodin and a telomerase inhibitor induces significant telomere damage/dysfunction and cell death.
Liu R; Liu J; Wang S; Wang Y; Zhang T; Liu Y; Geng X; Wang F
Cell Death Dis; 2019 Jul; 10(7):527. PubMed ID: 31296842
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells.
Bashash D; Zareii M; Safaroghli-Azar A; Omrani MD; Ghaffari SH
Hematology; 2017 Jul; 22(6):330-340. PubMed ID: 28054503
[TBL] [Abstract][Full Text] [Related]
7. Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies.
Biray Avci C; Dogan F; Ozates Ay NP; Goker Bagca B; Abbaszadeh Z; Gunduz C
J Cell Biochem; 2018 Dec; 119(12):9817-9824. PubMed ID: 30145821
[TBL] [Abstract][Full Text] [Related]
8. A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.
Shi Y; Sun L; Chen G; Zheng D; Li L; Wei W
Target Oncol; 2015 Dec; 10(4):565-73. PubMed ID: 25916999
[TBL] [Abstract][Full Text] [Related]
9. Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells.
Bashash D; Ghaffari SH; Mirzaee R; Alimoghaddam K; Ghavamzadeh A
Leuk Lymphoma; 2013 Mar; 54(3):561-8. PubMed ID: 22957790
[TBL] [Abstract][Full Text] [Related]
10. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines.
Parsch D; Brassat U; Brümmendorf TH; Fellenberg J
Cancer Invest; 2008 Jul; 26(6):590-6. PubMed ID: 18584350
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment.
Ward RJ; Autexier C
Mol Pharmacol; 2005 Sep; 68(3):779-86. PubMed ID: 15939802
[TBL] [Abstract][Full Text] [Related]
12. Telomerase activity in normal leukocytes and in hematologic malignancies.
Counter CM; Gupta J; Harley CB; Leber B; Bacchetti S
Blood; 1995 May; 85(9):2315-20. PubMed ID: 7727765
[TBL] [Abstract][Full Text] [Related]
13. Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.
Celeghin A; Giunco S; Freguja R; Zangrossi M; Nalio S; Dolcetti R; De Rossi A
Cell Death Dis; 2016 Dec; 7(12):e2562. PubMed ID: 28032863
[TBL] [Abstract][Full Text] [Related]
14. Telomerase inhibition on acute myeloid leukemia stem cell induced apoptosis with both intrinsic and extrinsic pathways.
Rafat A; Dizaji Asl K; Mazloumi Z; Movassaghpour AA; Talebi M; Shanehbandi D; Farahzadi R; Nejati B; Nozad Charoudeh H
Life Sci; 2022 Apr; 295():120402. PubMed ID: 35176279
[TBL] [Abstract][Full Text] [Related]
15. Role of p53 transcription factor in determining the efficacy of telomerase inhibitors in cancer treatment.
Gala K; Jain M; Shah P; Pandey A; Garg M; Khattar E
Life Sci; 2024 Feb; 339():122416. PubMed ID: 38216120
[TBL] [Abstract][Full Text] [Related]
16. Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line.
Pourbagheri-Sigaroodi A; Bashash D; Safaroghli-Azar A; Farshi-Paraasghari M; Momeny M; Mansoor FN; Ghaffari SH
Eur J Pharmacol; 2019 Mar; 846():49-62. PubMed ID: 30658112
[TBL] [Abstract][Full Text] [Related]
17. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
18. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia.
Sumi M; Tauchi T; Sashida G; Nakajima A; Gotoh A; Shin-Ya K; Ohyashiki JH; Ohyashiki K
Int J Oncol; 2004 Jun; 24(6):1481-7. PubMed ID: 15138591
[TBL] [Abstract][Full Text] [Related]
19. [The influence of compound aITEL1296 on telomerase activity and the growth of cancer cells].
Kovalenko NA; Zhdanov DD; Bibikova MV; Gotovtseva VIu
Biomed Khim; 2011; 57(5):501-10. PubMed ID: 22629600
[TBL] [Abstract][Full Text] [Related]
20. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
Rankin AM; Faller DV; Spanjaard RA
Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]